How to buy Amivantamab in China?

Amivantamab (Amivantamab) is a biologic drug used to treat certain patients with non-small cell lung cancer (NSCLC), especially those with specific genetic mutations.

Evantuzumab is not yet available in China, so patients cannot purchase it domestically and need to purchase it through foreign channels. There are only European versions of original drugs available abroad, and the price is relatively high, around 20,000 yuan.

Evantumumab belongs to the category of bispecific antibodies (Bi-specific Antibody). The drug was carefully designed to bind to two different molecular targets simultaneously: the epidermal growth factor receptor (EGFR) and the MET receptor. EGFR and MET play important roles in NSCLC and they promote tumor growth and spread. By inhibiting these two targets simultaneously, evantumumab can more effectively interfere with cancer cell signaling, thereby slowing tumor growth and spread.

The main indication of evantumumab is the treatment of EGFR Exon 20insertion mutation (EGFR Exon 20 Insertion Mutation)-positive advanced NSCLC. This specific mutation is rare in NSCLC but it is often insensitive to traditional EGFR inhibitor drugs, so treating these patients has been a challenge. The emergence of evantumumab fills this gap in treatment needs and provides patients with new treatment options.

Clinical trials have shown that evantumumab exhibits significant anti-tumor activity in EGFR Exon 20insertion mutation-positive NSCLC patients, including those who have received other treatments with limited efficacy. It can significantly extend the progression-free survival period, improve the patient's survival rate, and improve the patient's quality of life.

Like most medications, evantuzumab may cause some side effects, including fatigue, skin inflammation, nausea, and vomiting. Patients need to be regularly monitored and managed by a physician during treatment to minimize the occurrence and severity of these discomforts.